1. Hercbergs A. The thyroid gland as an intrinsic biological response modifier in advance neoplasia: a novel paradigm. In Vivo. 1996;10:245-248.
2.
2. Hercbergs A. Spontaneous remission of cancer: a thyroid hormone dependent phenomenon? Anticancer Res. 1999;19:4839-4844.
3.
3. Hercbergs AA, Goyal LK, Suh JH, et al. Propylthiouracilinduced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res. 2003;23(1B):617-626.
4.
4. Mukherjee P, El-Abbadi MM, Seyfried TN, et al. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer. 2002;86(10):1615-1621.
5.
5. Kokoglu E, Tuter Y, Sandikci KS, et al. Prostaglandin E2 levels in human brain tumor tissues and arachidonic acid levels in the plasma membrane of human brain tumors. Cancer Lett. 1998;132:17-21.
6.
6. Martin DD, Robbins ME, Spector AA, et al. The fatty acid composition of human gliomas differs from that found in nonmalignant brain tissue. Lipids. 1996;31:1283-1288.
7.
7. Castelli MG, Chiambrando C, Fanelli R, et al. Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res. 1989;49:1505-1508.
8.
8. Wallace JW. Nutritional and botanical modulation of the inflammatory cascade—eicosanoids, cyclooxygenases and lipoxygenses—as an adjunct in cancer therapy. Integr Cancer Ther. 2002;1(1):7-37.
9.
9. Galarraga J, Loreck DJ, Graham JF, et al. Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism. Metab Brain Dis. 1986;58:279-291.
10.
10. Hossmann KA, Keiburh I, Tamura M. Local cerebral blood flow and glucose consumption of rats with experimental gliomas. J Cerebral Blood Flow Metab. 1982;2:25-32.
11.
11. Seyfried TN, Sanderson TM, El-Abbadi MM, et al. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer. 2003;89(7):1375-1382.
12.
12. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000;60(17):4926-4931.
13.
13. Tatsuhiro J, et al. Differential expression of cyclooxygenase-2 (COX-2) in human gliomas and growth inhibition of glioma cell lines by COX-2 inhibitor in a three-dimensional culture system [abstract]. Proc Am Assoc Cancer Res. 2000;42:515.
14.
14. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygensae-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61(11):4375-4381.
15.
15. King JG, Khalili K. Inhibition of human brain tumor cell growth by the anti-inflammatory drug, flurbiprofen. Oncogene. 2001;20(47):6864-6870.
16.
16. Gati I, Bergstrom M, et al. Effects of the 5-lipoxygenase inhibitors AA-863 and U-60,257 on human glioma cell lines. Prostaglandins Leukot Essent Fatty Acids. 1990;40:117-124.
17.
17. Blomgren H, Kling-Andersson G. Growth inhibition of human malignant glioma cells in vitro by agents which interfere with biosynthesis of eicosanoids. Anticancer Res. 1992;26:981-986.
18.
18. Gati I, Bergstrom M, Westerberg G, et al. Effects of prostaglandin and leukotriene inhibitors on the growth of human glioma spheroids. Eur J Cancer. 1990;26:802-807.
19.
19. Wigmore SJ, MacMahon AJ, Sturgeon CM, Fearon KC. Acutephase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg. 2001;88(2):255-260.
20.
20. O’Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer. 2000;37(1):36-40.
21.
21. Kolebacz B. Concentrations of selected acute phase proteins and immunity immunoglobulins in the treatment of head and neck carcinomas. Otolaryngol Pol. 1999;53(6):743-746.
22.
22. Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995;75(8):2077-2082.
23.
23. Vellini M, Desideri D, Milanese A. Possible involvement of eicosanoids in the pharmacological action of bromelain. Arzneimittelforschung. 1986;36:110-112.
24.
24. Kelly GS. Bromelain: a literature review and discussion of its therapeutic applications. Alt Med Rev. 1996;1(4):243-257.
25.
25. Masson M. Bromelain in blunt injuries of the locomotor system: a study of observed applications in general practice. Fortschr Med. 1995;113(9):303-306.
26.
26. Tysnes BB, Maurer HR, Porwol T, et al. Bromelain extract from pineapple stem can control glioma invasion. Proc Soc Neurooncol, 6th Annual Meeting, Neurooncol. 2001;3(4 no. 234):324.
27.
27. Tysnes BB, Maurer HR, Porwol T, et al. Bromelain reversibly inhibits the invasive properties of glioma cells. Neoplasia. 2001;3(6):469-479.
28.
28. Safayhi H, Sailer ER, Ammon HP. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. 1995;47(6):1212-1216.
29.
29. Baba T, Chio CC, Black KL. The effect of 5-lipoxygenase inhibition on blood-brain barrier permeability in experimental brain tumors. J Neurosurg. 1992;77:403-406.
30.
30. Boeker DK, Winking M. The role of boswellic acids in the therapy of malignant glioma. Deutsches Aerzteblatt. 1997;94:A1197-A1199.
31.
31. Streffer JR, Bitzer M, Schabet M, Dichgans J, Weller M. Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15. Neurology. 2001;56(9):1219-1221.
32.
32. Janssen G, Bode U, Breu H, et al. Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. Klin Padiatr. 2000;212(4):189-195.
33.
33. Hostanska K, Daum G, Saller R. Cytostatic and apoptosisinducing activity of boswellic acids toward malignant cell lines in vitro. Anticancer Res. 2002;22(5):2853-2862.
34.
34. Winking M, Sarikaya S, et al. Boswellic acids inhibit glioma growth: a new treatment option? J Neurooncol. 2000;46(2):97-103.
35.
35. Glaser T, Winter S, Groscurth P, et al. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer. 1998;80(5/6):756-765.
36.
36. Lowell JA, Parnes HL, Blackburn GL. Dietary immunomodulation: beneficial effects on oncogenesis and tumor growth. Crit Care Med. 1990;18(suppl 2):S145-S148.
37.
37. Gramaglia A, Loi GF, Mongioj V, Baronzio GF. Increased survival in brain metastatic patients treated with stereotactic radiotherapy, omega-3 fatty acids and bioflavonoids. Anticancer Res. 1999;19(6C):5583-5586.
38.
38. Penglis PS, Cleland LG, Demasi M, Caughey GE, James MJ. Differential regulation of prostaglandin E2 and thromboxane A2 production in human monocytes: implications for the use of cyclooxygenase inhibitors. J Immunol. 2000;165(3):1605-1611.
39.
39. Goldman G, Welbourn R, Valeri CR, Shepro D, Hechtman HB. Thromboxane A2 induces leukotriene B4 synthesis that in turn mediates neutrophil diapedesis via CD18 activation. Microvasc Res. 1991;41(3):367-375.
40.
40. Teucher T, Obertreis B, Ruttkowski T, Schmitz H. Cytokine secretion in whole blood of healthy subjects following oral administration of Urtica dioica L. plant extract. Arzneimittelforschung. 1996;46(9):906-910.
41.
41. Obertreis B, Giller K, Teucher T, et al. Anti-inflammatory effect of Urtica dioica folia extract in comparison to caffeic malic acid. Arzeimittelforschung. 1996;46(1):52-56.
42.
42. Obertreis B, Ruttkowski T, Teucher T, et al. Ex-vivo in-vitro inhibition of lipopolysaccharide stimulated tumor necrosis factor-alpha and interleukin-1 beta secretion in human whole blood by extractum urticae dioicae foliorum. Arzneimittelforschung. 1996;46(4):936.
43.
43. Monje M, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302(5651):1689-1690.
44.
44. Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anti-copper, antiangiogenic agents: phase I study. Clin Cancer Res. 2000;6(1):1-10.
45.
45. Turecky L, Kalina P, Uhlikova E, et al. Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin Wochenschr. 1984;158:187-189.
46.
46. Rao GM, Rao AV, Raja A, et al. Role of antioxidant enzymes in brain tumors. Clin Chim Acta. 2000;296(1-2):203-212.
47.
47. Brem SS, Zagzag D, Tsanaclis AM, Gately S, Elkouby MP, Brien SE. Inhibition of angiogenesis and tumor growth in the brain. Am J Pathol. 1990;137(5):1121-1142.
48.
48. Brem S, Tsanaclis AM, Zagzag D. Anticopper treatment inhibits pseudopodial protrusion and the invasive spread of 9L gliosarcoma cells in the rat brain. Neurosurgery. 1990;32:391-396.
49.
49. Yoshida D, Ikeda Y, Nakazawa S. Suppression of 9L gliosarcoma growth by copper depletion with copper-deficient diet and Dpenicillamine. J Neurooncol. 1993;17(2):91-97.
50.
50. Philipov P. Suppression of tumor growth in experimental 9L gliosarcoma model by copper depletion. Neurol Med Chir (Tokyo). 1996;36(2):115-116.
51.
51. Vanchieri C. Cutting copper curbs angiogenesis, studies show. J Natl Cancer Inst. 2000;92(15):1202-1203.
52.
52. Merchant RE, Rice CD, Young HF. Dietary Chlorella pyrenoidosa for patients with malignant glioma: effects on immunocompetence, quality of life, and survival. Phytother Res. 1991;4(6):220-231.
53.
53. Engebraaten O, Bjerkvig R, Berens M. Effect of alkyllysophospholipid on glioblastoma cell invasion into fetal rat brain tissue in vitro. Cancer Res. 1991;51:1713-1719.
54.
54. Annabi B, Lachambre MP, Bousquet-Gagnon N, et al. Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochim Biophys Acta. 2002;1542(1-3):209-220.
55.
55. Sachinidis A, Seul C, Seewald S, et al. Green tea compounds inhibit tyrosine phosphorylation of PDGF beta-receptor and transformation of A172 human glioblastoma. FEBS Lett. 2000;471(1):51-55.
56.
56. Ahn HY, Hadizadeh KR, Seul C, et al. Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172). Mol Biol Cell. 1999;10(4):1093-1104.
57.
57. Yokoyama S, Hirano H, Wakimaur N, et al. Inhibitory effect of epigallocatechin-gallate on brain tumor cell lines in vitro. Neuro-oncol. 2001;3(1):22-28.
58.
58. Serenelli G, Petturiti G, Tognellini R, et al. Apoptosis induced in glioma rat cells cultivated in the presence of a medicinal infusion of green tea. Eur J Histochem. 1997;41(suppl 2):85-86.
59.
59. Iwasa K, Moriyasu M, Yamori T, et al. In vitro cytotoxicity of the proto-berberine type alkyloids. J Nat Prod. 2001;64(7):896-898.
60.
60. Sanders MM, Liu AA, Li TK, et al. Selective cytotoxicity of topoisomerase-directed proto-berberines against glioblastoma cells. Biochem Pharmacol. 1998;56(9):1157-1166.
61.
61. Chen KT, Hao DM, Liu ZX, et al. Effect of berberine alone or in combination with argon ion laser treatment on 9L rat glioma cell line. Chin Med J (Engl). 1994;107(11):808-812.
62.
62. Zhang RX, Dougherty DV, Rosenblum ML. Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors. Chinese Med J. 1990;103(8):658-665.
63.
63. Naveilhan P, Berger F, Haddad K, et al. Induction of glioma cell death by 1,25(OH)2vitaminD3: towards an endocrine therapy of brain tumors? J Neurosci Res. 1994;37:271-277.
64.
64. Baudet C, Chevalier G, Naveilhan P, et al. Cytotoxic effects of 1-alpha,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line. Cancer Lett. 1996;100:3-10.
65.
65. Baudet C, Chevalier G, Chassevent A, et al. 1,25-dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line. J Neurosci Res. 1996;46:540-550.
66.
66. Trouillas P, Honnorat J, Bret P, et al. Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol. J Neuro-Oncology. 2001;51:57-66.
67.
67. Lisianyi NI, Markova OV, Zhmareva EN. Activity of the natural killer cells in the peripheral blood of patients with brain tumors [Russian]. Eksp Onkol. 1988;10:57-59.
68.
68. Heuser G, Vojdani A. Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals. Immunopharmacol Immunotoxicol. 1997;19(3):291-312.
69.
69. Chatterjee S, Banerji TK. Effects of melatonin on the growth of MtT/F4 anterior pituitary tumor: evidence for inhibition of tumor growth dependent upon the time of administration. J Pineal Res. 1989;7(4):381-391.
70.
70. Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 1996;53(1):43-46.
71.
71. Lissoni P, Giani L, Zerbini S, et al. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat Immun. 1998;16(1):27-33.
72.
72. Lissoni P, Rovelli F, Meregalli S, et al. Melatonin as a new possible anti-inflammatory agent. J Biol Regul Homeost Agents. 1997;11(4):157-159.
73.
73. Lissoni P, Barni S, Mandala M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 1999;35(12):1688-1692.
74.
74. Lissoni P, Tancini G, Barni S, et al. Treatment of cancer chemotherapy-induced toxicity with pineal hormone melatonin. Support Care Cancer. 1997;5(2):126-129.
75.
75. Vivani S, Negretti E, Orazi A, et al. Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy. J Pineal Res. 1990;8(4):347-354.
76.
76. Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res. 1997;23(1):15-19.
77.
77. Fauteck J, Schmidt H, Lerchl A, et al. Melatonin in epilepsy: first results of replacement therapy and first clinical results. Biol Signals Recept. 1999;8(1-2):105-110.
78.
78. Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G. Supplementation with selenium and human immune cell functions: II. Effect on cytotoxic lymphocytes and natural killer cells [published correction appears in Biol Trace Elem Res. 1994;46:183]. Biol Trace Elem Res. 1994;41:115-127.
79.
79. Zhang ZH, Kimura M, Itokawa Y. Inhibitory effect of selenium and change of glutathione peroxidase activity on rat glioma. Biol Trace Elem Res. 1996;55:31-38.
80.
80. Philipov P, Tzatchev K. Selenium in the treatment of patients with brain gliomas: a pilot study. Zentralbl Neurochir. 1990;51:145-146.
81.
81. Pakdaman A. Symptomatic treatment of brain tumor patients with sodium selenite, oxygen, and other supportive measures. Biol Trace Elem Res. 1998;62:1-6.
82.
82. Wallace JM. A model for drug-nutrient synergies: focus on corticosteroid drugs. Int J Integrative Med. 2000;2(5):33-39.
83.
83. Bergamini L, Mutani R, Delsedime M, Durelli L. First clinical experience on the antiepileptic action of taurine. Eur Neurol. 1974;11(5):261-269.
84.
84. Desai TK, Maliakkal J, Kinzie JL, Ehrinpreis MN, Luk GD, Cejka J. Taurine deficiency after intensive chemotherapy and/or radiation. Am J Clin Nutr. 1992;55(3):708-711.
85.
85. Abe M, Takahashi M, Takeuchi K, Fukuka M. Studies on the significance of taurine in radiation injury. Radiation Res. 1968;33:563-573.
86.
86. Fukuda T, Abe K, Takeuchi K, Imura T. Studies on the restorative effect of taurine on leukopenia induced by radiation therapy. Nippon Igaku Hoshasen Gakki Zasshi. 1968;28:959-966.
